1,020 filings
Page 15 of 51
8-K
hmwiql08vc0q sbd8kt
27 Jan 20
Other Events
10:59am
8-K
2czxuouj
21 Jan 20
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
10:09am
8-K
yktfrgxpzs7fowx
13 Jan 20
Trovagene Oncology Investor Presentation January 2020
10:22am
4
1q4ushtbru
3 Jan 20
Trovagene / Mark Erlander ownership change
4:15pm
4
894a1qkrbi0z ez9
3 Jan 20
Trovagene / Mark Erlander ownership change
4:10pm
8-K
xmabl omzmp
9 Dec 19
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
2:49pm
8-K
xoz3p7c
4 Dec 19
Other Events
12:15pm
424B3
lfmfrz4 qhra5ye
14 Nov 19
Prospectus supplement
12:14pm
8-K
1m6lhja
14 Nov 19
Other Events
9:07am
EFFECT
a5v0mql
14 Nov 19
Notice of effectiveness
12:15am
UPLOAD
ovb3i23luau2a rn
12 Nov 19
Letter from SEC
12:00am
CORRESP
x95a x9uztk6s4kuex
12 Nov 19
Correspondence with SEC
12:00am
8-K
d3qgho2h5
7 Nov 19
Trovagene Announces Third Quarter 2019 Results and Highlights
4:21pm
8-K
ey6ta46
6 Nov 19
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
12:41pm
SC 13G
tiqj1lnq3zlppqoh5
4 Nov 19
Trovagene, Inc.
12:00am
SC 13G
do3j tn5o
1 Nov 19
Trovagene, Inc.
4:10pm